KAPOSIFORM HEMANGIOENDOTHELIOMA: 2 RARE CASES REPORT OF THE VIETNAM NATIONAL CHILDREN’S HOSPITAL
##plugins.themes.vojs.article.main##
Abstract
Kaposiform hemangioendothelioma (KHE) is a rare and locally aggressive endothelial neoplasm in children, progresses rapidly, able to cause severe anemia. The tumours can occur in soft subcutaneous tissue and noncutaneous sites such as the liver and pancreas. We report two cases of a male and a female infant with a large tumour in the right arm - forearm area, both prenting with thrombocytopenic anemia. Needle biopsies were performed, combined histology and IHC to confirm the diagnosis of KHE. Medical treatment with Vincristine, Aspirin and Propranolol has led to good result, demonstrated by the tumours stopping progression and reducing volume soon after the first treatment course.
##plugins.themes.vojs.article.details##
Keywords
hemangioendothelioma, Kaposi, KHE
References
2. Lyons LL, North PE, Lai FMM et al.Kaposiform hemangioendothelioma: a study of 33 cases emphasizing its pathologic, immunophenotypic, and biologic uniqueness from juvenile hemangioma. Am J Surg Pathol 2004;28(5):559-68. https://doi.org/10.1097/00000478-200405000-00001
3. Mulliken JB, Anupindi S, Ezekowwitz RAB et al. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 13-2004. A newborn girl with a large cutaneous lesion, thrombocytopenia, and anemia. N Engl J Med 2004;350(17):1764-75. https://doi.org/10.1056/nejmcpc049002
4. Schaefer BA, Wang D, Merrow AC et al. Long-term outcome for kaposiform hemangioendothelioma: A report of two cases. Pediatr Blood Cancer 2017;64(2):284-86. https://doi.org/10.1002/pbc.26224
5. Fernandez-Pineda I, Lopez-Gutierrez JC, Chocarro G et al. Long-term outcome of vincristine-aspirin-ticlopidine (VAT) therapy for vascular tumors associated with Kasabach-Merritt phenomenon. Pediatr Blood Cancer 2013;60(9):1478-81. https://doi.org/10.1002/pbc.24543
6. Croteau SE, Liang MG, Kozakewich HP et al. Kaposiform hemangioendothelioma: atypical features and risks of Kasabach-Merritt phenomenon in 107 referrals. J Pediatr 2013;162(1):142-7. https://doi.org/10.1016/j.jpeds.2012.06.044
7. Ji Y, Yang K, Peng S et al. Kaposiform haemangioendothelioma: clinical features, complications and risk factors for Kasabach-Merritt phenomenon. Br J Dermatol 2018;179(2):457-463. https://doi.org/10.1111/bjd.16601
8. Adams DM, Brandão LR, Peterman CM et al. Vascular anomaly cases for the Pediatric hematologist oncologists-An interdisciplinary review. Pediatr Blood Cancer 2018;65(1).https://doi.org/10.1002/pbc.26716
9. Mahajan P, Margolin J, Iacobas I. Kasabach-Merritt Phenomenon: Classic Presentation and Management Options. Clin Med Insights Blood Disord 2017;10: 1179545X17699849.https://doi.org/10.1177/1179545x17699849
10. Dadras SS, Skzypek A, Nguyen L et al. Prox-1 promotes invasion of kaposiform hemangioendotheliomas. J Invest Dermatol 2008;128(12):2798-806.https://doi.org/10.1038/jid.2008.176
11. Weiss SW. Kaposiform Hemangioendothelioma. WHO Classification of Tumours of Soft Tissue and Bone, B. Fletcher and M. Hogendoorn, Eds., 2013:145-146.
12. Borst AJ, Eng W, Griffin M et al. Treatment practices and response in kaposiform hemangioendothelioma: A multicenter cohort study. Pediatr Blood Cancer 2024;71(3):e30779. https://doi.org/10.1002/pbc.30779
13. D. Adams and I. Frieden. Tufted angioma, kaposiform hemangioendothelioma, and the Kasabach-Merritt phenomenon. UpToDate 2017.
14. Liu XH, Li JY, Qu XH et al. Treatment of kaposiform hemangioendothelioma and tufted angioma. Int J Cancer 2016;139(7):1658-66. https://doi.org/10.1002/ijc.30216.